Background It would be convenient to 'be able to measure airway responsiveness to histamine and to bronchodilator drugs on the same day, but whether this can be done reliably is unknown. Methods The effect of a prior histamine challenge on the bronchodilator response to salbutamol after spontaneous recovery of FEV, to 95% of the prechallenge level was studied in two groups of asthmatic children. Fourteen children inhaled 400 pg salbutamol after spontaneous recovery from a histamine challenge, followed by a further 100 pg salbutamol 20 FVC of 60-75%, or both; (3) dose of histamine that reduced FEV, by 20% (PD20) less than 150 jg; (4) ability to perform forced expiratory manoeuvres reproducibly; (5) age 7-14 years. All medication was discontinued before the tests (eight hours in advance for inhaled drugs and 48 hours for oral drugs). The study was carried out with the informed consent of both children and parents, and was approved by the local medical ethics committee.
inhaled 400 pg salbutamol after spontaneous recovery from a histamine challenge, followed by a further 100 pg salbutamol 20 minutes later. In a second group of eight asthmatic children the study was repeated with 800 pg salbutamol, followed by a further 200 pg 20 minutes later.
Results After histamine challenge FEV, returned to baseline in 70 minutes or less on all occasions. The FEV, 20 minutes after 400 pg salbutamol was significantly lower after the histamine challenge than on the control day. After the further 100 pg salbutamol FEV, values were similar after the histamine challenge and on the control day. FEV, values after 800 pg salbutamol and the further 200 pg dose were not influenced by a prior histamine challenge. Conclusions In children with stable asthma in whom FEV, has returned to baseline after a histamine challenge the FEV, achieved after 800 pg salbutamol is not affected by the histamine challenge. Histamine Aerosolised histamine diphosphate was inhaled from a calibrated DeVilbiss 646 nebuliser with its vent closed and primed with 3 ml solution. The nebuliser was attached to a Rosenthal-French dosimeter driven by air at 137-8 kPa (20 lb/in2). The aerosol was delivered directly into the mouth through a mouth tube. The subject inspired as slowly as possible from functional residual capacity to total lung capacity. During the inspiration the dosimeter was triggered for 0-6 seconds. At the end of the inspiration the children were asked to hold their breath for about two seconds. With this technique lung deposition should be maximal.'3 A total of 20 Ml of histamine solution was delivered to the mouth in four consecutive breaths. Histamine diphosphate in buffered saline was given in doubling concentrations (0-25-32 mg/ml). PD20 was calculated by interpolation of the dose-response curve on a log-linear scale.'4 STUDY PROTOCOLS Protocol 1
Children were investigated in a randomised crossover design at about the same time of the day on two days within two weeks. On the control day a baseline measurement of FEV1 was followed by four inhalations of 100 jg salbutamol and a further measurement of FEV, 20 minutes later. A further 100 jg salbutamol was then administered and FEV1 measured again after 20 minutes. On the histamine challenge day baseline measurement of FEV, (baseline 1) was followed by a histamine challenge test until FEV, fell by 20%. FEV1
was then allowed to recover spontaneously. Recovery was monitored 60 and 70 minutes after the end of the histamine challenge. It was regarded as complete when FEV1 had returned to at least 95% of baseline 1 in 70 minutes (baseline 2). Seventy minutes after the histamine challenge the two step bronchodilatation was measured as on the control day. Subjects were excluded when complete recovery was not achieved, or when the baseline FEV1 measurement on the first day differed more than 10% from that on the second day.
Protocol 2
The design was the same as in protocol 1, except that twice as much salbutamol was administered, puffs of Of the 19 children who took part in the study, five failed to complete it, three for personal reasons and two because FEVy recordings on the second day differed by more than 10% from those on the first day. Nine boys and five girls (age range 8-1-13-5 years) completed protocol 1 (table 1) . FEVy had returned to baseline values in 11 children within 60 minutes, and in all after 70 minutes. There were no significant differences between baseline 1 and 2 FEV, values before and after histamine (mean difference -0-2% predicted, 95% CL -2-5, 2 2), or between baseline on the control day and baseline 1 on the histamine challenge day (mean difference 0 5% predicted, 95% CL -1 1, 2.2) or baseline 2 on the histamine challenge day (mean difference 0 4 % predicted, 95% CL -2-0, 2-8).
Twenty minutes after administration of 400 jg salbutamol FEV1 was significantly smaller on the histamine challenge day than on the control day (mean difference -4-2% predicted, 95% CL -74, -0-9; p = 0-016).
After a further 100 jg salbutamol FEV1 did not differ from that on the control day (mean difference -0-77% predicted, 95% CL -34, 40-from mast cells'9; there is no evidence that f2 eline 2) agonists reverse airway oedema, though they Time (min) may prevent its development. 20 The influence of A2 agonists on microvascular leakage and oedema of the airway wall has been studied between baseline 1 and 2 only in animals, with conflicting reports, the aine (mean difference 1 0 findings varying with the species studied.'72122 L-117, 3 8) 
or between
Results from protocol 1 suggest that after a )l day and baseline 1 on histamine challenge the same plateau of FEV1 ge day (mean difference % predicted is reached as on the control day 5% CL -5.3, 2*4) or but it is reached more slowly; this may reflect iistamine challenge day problems of bronchodilator access to parts of 4% predicted, 95% CL the bronchial tree and subsequent indirect ecovered spontaneously delivery through the bronchial circulation.23 It ill children. Administra-is also possible that residual effects of the tamol on the histamine previous histamine challenge antagonise the in an FEV, value similar response to salbutamol. This could explain Ltrol day (mean difference why the histamine challenge had no effect on the l% CL -59, 1 9), with bronchodilator response when the dose of )nse to the final 200 jg salbutamol was doubled in the experiments in rence -1-2 % predicted, protocol 2. This is compatible with the Changes in FEV1 on the observation that incubation of human lung , none of the differences tissue with histamine concentrations greater nificance. than 10 ,umol/l induces release of bronchoconstricting (PGF2,) and bronchodilating prostaglandins (PGE)2126; these in turn can stimulate mast cells to release bronchodilating and bronto address the influence of choconstricting prostaglandins.25 Circulating )n test on bronchodilata-levels of prostaglandins remain raised for over Is recovery from such a 35 minutes,2527 corresponding with the time i suggested that pulmo-airway calibre remains diminished when asthsuch as assessment of matic patients inhale these prostaglandins.28 n be performed after a Estimates, on the assumption of an average vhen FEV, has returned thickness of the pericellular fluid layer of lue. 8 We investigated the 5-6 jm29 and calculated by a method analogous mine challenge on bron-to that used for terbutaline,30 suggest that those ilbutamol after sponta-in vitro concentrations of histamine are similar EV, order to assess the to those used in our experiments. Hence ing the two tests reliably mediators released during a histamine iough FEV1 after 400 jg challenge may affect the recovery of FEV1, and icantly diminished by a may in part explain why more f2 agonist is nge this was not the case needed even after spontaneous recovery of ;had been administered. FEV1 to obtain the same response as that seen aol was inhaled instead of without a prior histamine challenge. Because a ?rior histamine challenge maximal effect was obtained a dose higher than ncrease in FEV1 due to the one we used seems unnecessary. After as smaller on the hista-inhalation of this dose of salbutamol we han on the control day observed a transient tremor in most children, as istamine FEV1, and that occurs in adults, 3' 
